Ireland's Perrigo Q4 revenue slightly beats

Reuters02-26
Ireland's Perrigo Q4 revenue slightly beats

Overview

  • Consumer health product provider's Q4 revenue slightly beat analyst expectations

  • Adjusted EPS for Q4 missed analyst expectations

  • Company launching operational enhancement program to deliver $80 mln to $100 mln savings

Outlook

  • Perrigo sees FY2026 net sales down 5.5% to 1.5%

  • Perrigo expects FY2026 adjusted EPS of $2.00 to $2.30

  • Perrigo anticipates CORE FY2026 EPS of $2.25 to $2.55

Result Drivers

  • INFANT FORMULA IMPACT - Organic net sales decline primarily due to lower sales in infant formula, impacting overall performance

  • MARKET SHARE GAINS - Despite soft OTC category consumption, Perrigo gained share in store brands and key brands

  • COST SAVINGS - Project Energize and Supply Chain Reinvention Program delivered significant cost savings, partially offsetting lower gross profit

Company press release: ID:nPn7XvX6Ra

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

Slight Beat*

$1.11 bln

$1.10 bln (3 Analysts)

Q4 Adjusted EPS

Miss

$0.77

$0.79 (3 Analysts)

Q4 EPS

-$10.20

Q4 Adjusted Net Income

Miss

$108 mln

$120.83 mln (3 Analysts)

Q4 Net Income

-$1.41 bln

Q4 Adjusted Operating Income

Miss

$167 mln

$188.53 mln (3 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Perrigo Company PLC is $18.00, about 24.9% above its February 25 closing price of $14.41

  • The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 7 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment